ARROWHEAD PHARMACEUTICALS, INC. Income Taxes Paid
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) reported Income Taxes Paid of $21.59 million for the 9-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:IncomeTaxesPaidNet · last filed 2026-08-04
- ARROWHEAD PHARMACEUTICALS, INC. income taxes paid, net for the quarter ending 2026-06-30 was $22.00K.
- ARROWHEAD PHARMACEUTICALS, INC. income taxes paid, net for the quarter ending 2026-03-31 was $11.66M, a 16554.29% increase year-over-year.
- ARROWHEAD PHARMACEUTICALS, INC. income taxes paid, net for the quarter ending 2025-12-31 was $9.91M, a 89963.64% increase year-over-year.
- ARROWHEAD PHARMACEUTICALS, INC. income taxes paid, net for the quarter ending 2025-09-30 was $733.00K.
- ARROWHEAD PHARMACEUTICALS, INC. income taxes paid, net for fiscal 2025 was $814.00K.
- ARROWHEAD PHARMACEUTICALS, INC. income taxes paid, net for fiscal 2024 was -$3.74M.
- ARROWHEAD PHARMACEUTICALS, INC. income taxes paid, net for fiscal 2023 was $0.00.
- ARROWHEAD PHARMACEUTICALS, INC. income taxes paid, net for fiscal 2022 was -$2.00K.
| Period end | Income Taxes Paid, Net 3 month | Income Taxes Paid, Net 3 month as first filed | Income Taxes Paid, Net 6 month | Income Taxes Paid, Net 6 month as first filed | Income Taxes Paid, Net 9 month | Income Taxes Paid, Net 9 month as first filed | Income Taxes Paid, Net 12 month | Income Taxes Paid, Net 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $22.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-08-04 | $11.68M derived: sum of 2 quarters · filed 2026-08-04 | $21.59M 10-Q · filed 2026-08-04 | $22.32M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2026-03-31 | $11.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-05-07 | $21.57M 10-Q · filed 2026-05-07 | $22.30M derived: sum of 3 quarters · filed 2026-05-07 | $22.30M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-12-31 | $9.91M 10-Q · filed 2026-02-05 | $10.64M derived: sum of 2 quarters · filed 2026-02-05 | $10.64M derived: sum of 3 quarters · filed 2026-08-04 | $10.71M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-09-30 | $733.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-25 | $733.00K derived: sum of 2 quarters · filed 2026-08-04 | $803.00K derived: sum of 3 quarters · filed 2026-08-04 | $814.00K 10-K · filed 2025-11-25 | ||||
| 2025-06-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2026-08-04 | $70.00K derived: sum of 2 quarters · filed 2026-08-04 | $81.00K 10-Q · filed 2026-08-04 | -$6.72M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-03-31 | $70.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-05-07 | $81.00K 10-Q · filed 2026-05-07 | -$6.72M derived: sum of 3 quarters · filed 2026-05-07 | -$6.68M derived: sum of 4 quarters · filed 2026-05-07 | ||||
| 2024-12-31 | $11.00K 10-Q · filed 2026-02-05 | -$11.00K 10-Q · filed 2025-02-10 | -$6.79M derived: sum of 2 quarters · filed 2026-02-05 | -$6.75M derived: sum of 3 quarters · filed 2026-02-05 | -$2.73M derived: sum of 4 quarters · filed 2026-02-05 | |||
| 2024-09-30 | -$6.81M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-25 | -$6.76M derived: sum of 2 quarters · filed 2025-11-25 | -$2.75M derived: sum of 3 quarters · filed 2025-11-25 | -$3.74M 10-K · filed 2025-11-25 | ||||
| 2024-06-30 | $48.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-08-07 | $4.06M derived: sum of 2 quarters · filed 2025-08-07 | $3.06M 10-Q · filed 2025-08-07 | -$3.06M 10-Q · filed 2024-08-08 | $3.06M derived: sum of 4 quarters · filed 2025-11-25 | |||
| 2024-03-31 | $4.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-05-12 | $3.01M 10-Q · filed 2025-05-12 | -$3.01M 10-Q · filed 2024-05-09 | $3.01M derived: sum of 3 quarters · filed 2025-11-25 | $3.01M derived: sum of 4 quarters · filed 2025-11-25 | |||
| 2023-12-31 | -$999.00K 10-Q · filed 2025-02-10 | -$999.00K derived: sum of 2 quarters · filed 2025-11-25 | -$999.00K derived: sum of 3 quarters · filed 2025-11-25 | -$999.00K derived: sum of 4 quarters · filed 2025-11-25 | ||||
| 2023-09-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-25 | $0.00 derived: sum of 2 quarters · filed 2025-11-25 | $0.00 derived: sum of 3 quarters · filed 2025-11-25 | $0.00 10-K · filed 2025-11-25 | ||||
| 2023-06-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-08-08 | $0.00 derived: sum of 2 quarters · filed 2024-08-08 | $0.00 10-Q · filed 2024-08-08 | -$2.00K derived: sum of 4 quarters · filed 2024-11-26 | ||||
| 2023-03-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-05-09 | $0.00 10-Q · filed 2024-05-09 | -$2.00K derived: sum of 3 quarters · filed 2024-11-26 | -$2.00K derived: sum of 4 quarters · filed 2024-11-26 | ||||
| 2022-12-31 | $0.00 10-Q · filed 2024-02-06 | -$2.00K derived: sum of 2 quarters · filed 2024-11-26 | -$2.00K derived: sum of 3 quarters · filed 2024-11-26 | -$2.00K derived: sum of 4 quarters · filed 2024-11-26 | ||||
| 2022-09-30 | -$2.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-11-26 | -$2.00K derived: sum of 2 quarters · filed 2024-11-26 | -$2.00K derived: sum of 3 quarters · filed 2024-11-26 | -$2.00K 10-K · filed 2024-11-26 | ||||
| 2022-06-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-08-07 | $0.00 derived: sum of 2 quarters · filed 2023-08-07 | $0.00 10-Q · filed 2023-08-07 | |||||
| 2022-03-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-05-02 | $0.00 10-Q · filed 2023-05-02 | ||||||
| 2021-12-31 | $0.00 10-Q · filed 2023-02-06 | |||||||
| 2021-09-30 | -$2.00K 10-K · filed 2023-11-29 | |||||||
| 2020-09-30 | $103.00K 10-K · filed 2022-11-28 | $103.44K 10-K · filed 2020-11-23 | ||||||
| 2019-09-30 | -$302.00K 10-K · filed 2021-11-22 | -$302.40K 10-K · filed 2020-11-23 | ||||||
| 2018-09-30 | -$2.40K 10-K · filed 2020-11-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |